Operating Segments (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Summary of segmental information
Revenues, principally from grants	$ 312,491	$ 931,627	$ 1,845,123	$ 2,341,896
Income (Loss) from Operations	(1,860,662)	(760,216)	(5,704,443)	(3,182,883)
Amortization and Depreciation Expense	58,100	64,032	171,666	172,785
Other Income /(Expense), Net	652	1,250	1,438	5,284
Stock-Based Compensation	406,891	147,772	571,171	382,774
Identifiable Assets	7,650,047		7,650,047		4,705,104
Vaccines/BioDefense [Member]
Summary of segmental information
Revenues, principally from grants	264,920	862,919	1,683,265	2,170,761
Income (Loss) from Operations	(419,929)	19,190	(1,983,396)	(111,319)
Amortization and Depreciation Expense	28,316	31,357	83,951	84,308
Stock-Based Compensation	39,493	29,103	61,742	33,363
Identifiable Assets	442,407		442,407		628,494
BioTherapeutics [Member]
Summary of segmental information
Revenues, principally from grants	47,571	68,708	161,858	171,135
Income (Loss) from Operations	(1,080,436)	(155,713)	(2,068,703)	(1,363,572)
Amortization and Depreciation Expense	29,233	32,180	86,303	86,913
Stock-Based Compensation	158,142	(49,275)	205,083	63,339
Identifiable Assets	411,847		411,847		566,111
Corporate [Member]
Summary of segmental information
Income (Loss) from Operations	(360,297)	(623,693)	(1,652,344)	(1,707,992)
Amortization and Depreciation Expense	551	495	1,412	1,564
Other Income /(Expense), Net	(4,699,194)	1,250	(5,347,984)	5,284
Stock-Based Compensation	209,256	167,944	304,346	286,072
Identifiable Assets	$ 6,795,793		$ 6,795,793		$ 3,510,499